Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2014. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding increases in their ordinary shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed is the share purchase price of 1411.09 pence per share.
Material Changes
The filing details increases in personal shareholdings for nine executives following the re-investment of dividends paid on October 2, 2014. The transactions occurred on October 3, 2014. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is strictly a regulatory disclosure of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares acquired by each listed director through dividend re-investment.
- Confirm the share price of 1411.09 pence per share used for the October 3, 2014 transactions.
- Note that this filing does not contain quarterly or annual financial performance data.